Dare Bioscience, Inc. (DARE) Form 8-K — Oct 2, 2026
Daré Bioscience received a Nasdaq deficiency letter on September 28, 2026 because its closing bid price was below $1.00 for 30 consecutive business days, violating the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice has no immediate effect on DARE's listing. Nasdaq granted the company until March 29, 2027 to regain compliance, which requires a closing bid of at least $1.00 for 10 consecutive business days.
Key figures
- Cure period days
- 180
- Compliance deadline
- 2027-03-29
- Minimum bid requirement
- $1.00
- Consecutive days below minimum
- 30
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.